Evidence map›Paper›PMID 29074585›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2018

Δ-5 Fatty Acid Desaturase

Anthony D Gromovsky, Rebecca C Schugar, Amanda L Brown, Robert N Helsley, Amy C Burrows, Daniel Ferguson, Renliang Zhang, Brian E Sansbury, Richard G Lee, Richard E Morton and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Polyunsaturated fatty acid metabolism in the retinal pigment epithelium and its association with outer retinal disease.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Review
  4. Observational
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Hepatocyte-SpecificInternational journal of molecular sciences · 2024
    Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Anthony D GromovskyFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute (A.D.G., R.C.S., A.L.B., R.N.H., A.C.B., D.F., R.Z., R.E.M., J.M.B.) and Department of Anatomical Pathology (D.S.A.), Cleveland Clinic, OH; Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (B.E.S., M.S.); Cardiovascular Group, Antisense Drug Discovery, Ionis Pharmaceuticals, Inc, Carlsbad, CA (R.G.L.); and Department of Internal Medicine-Section on Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.S.P.).
Rebecca C SchugarFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute (A.D.G., R.C.S., A.L.B., R.N.H., A.C.B., D.F., R.Z., R.E.M., J.M.B.) and Department of Anatomical Pathology (D.S.A.), Cleveland Clinic, OH; Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (B.E.S., M.S.); Cardiovascular Group, Antisense Drug Discovery, Ionis Pharmaceuticals, Inc, Carlsbad, CA (R.G.L.); and Department of Internal Medicine-Section on Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.S.P.).
Amanda L BrownFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute (A.D.G., R.C.S., A.L.B., R.N.H., A.C.B., D.F., R.Z., R.E.M., J.M.B.) and Department of Anatomical Pathology (D.S.A.), Cleveland Clinic, OH; Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (B.E.S., M.S.); Cardiovascular Group, Antisense Drug Discovery, Ionis Pharmaceuticals, Inc, Carlsbad, CA (R.G.L.); and Department of Internal Medicine-Section on Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.S.P.).
Robert N HelsleyFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute (A.D.G., R.C.S., A.L.B., R.N.H., A.C.B., D.F., R.Z., R.E.M., J.M.B.) and Department of Anatomical Pathology (D.S.A.), Cleveland Clinic, OH; Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (B.E.S., M.S.); Cardiovascular Group, Antisense Drug Discovery, Ionis Pharmaceuticals, Inc, Carlsbad, CA (R.G.L.); and Department of Internal Medicine-Section on Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.S.P.).
Amy C BurrowsFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute (A.D.G., R.C.S., A.L.B., R.N.H., A.C.B., D.F., R.Z., R.E.M., J.M.B.) and Department of Anatomical Pathology (D.S.A.), Cleveland Clinic, OH; Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (B.E.S., M.S.); Cardiovascular Group, Antisense Drug Discovery, Ionis Pharmaceuticals, Inc, Carlsbad, CA (R.G.L.); and Department of Internal Medicine-Section on Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.S.P.).
Daniel FergusonFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute (A.D.G., R.C.S., A.L.B., R.N.H., A.C.B., D.F., R.Z., R.E.M., J.M.B.) and Department of Anatomical Pathology (D.S.A.), Cleveland Clinic, OH; Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (B.E.S., M.S.); Cardiovascular Group, Antisense Drug Discovery, Ionis Pharmaceuticals, Inc, Carlsbad, CA (R.G.L.); and Department of Internal Medicine-Section on Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.S.P.).
Renliang ZhangFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute (A.D.G., R.C.S., A.L.B., R.N.H., A.C.B., D.F., R.Z., R.E.M., J.M.B.) and Department of Anatomical Pathology (D.S.A.), Cleveland Clinic, OH; Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (B.E.S., M.S.); Cardiovascular Group, Antisense Drug Discovery, Ionis Pharmaceuticals, Inc, Carlsbad, CA (R.G.L.); and Department of Internal Medicine-Section on Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.S.P.).
Brian E SansburyFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute (A.D.G., R.C.S., A.L.B., R.N.H., A.C.B., D.F., R.Z., R.E.M., J.M.B.) and Department of Anatomical Pathology (D.S.A.), Cleveland Clinic, OH; Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (B.E.S., M.S.); Cardiovascular Group, Antisense Drug Discovery, Ionis Pharmaceuticals, Inc, Carlsbad, CA (R.G.L.); and Department of Internal Medicine-Section on Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.S.P.).
Richard G LeeFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute (A.D.G., R.C.S., A.L.B., R.N.H., A.C.B., D.F., R.Z., R.E.M., J.M.B.) and Department of Anatomical Pathology (D.S.A.), Cleveland Clinic, OH; Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (B.E.S., M.S.); Cardiovascular Group, Antisense Drug Discovery, Ionis Pharmaceuticals, Inc, Carlsbad, CA (R.G.L.); and Department of Internal Medicine-Section on Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.S.P.).
Richard E MortonFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute (A.D.G., R.C.S., A.L.B., R.N.H., A.C.B., D.F., R.Z., R.E.M., J.M.B.) and Department of Anatomical Pathology (D.S.A.), Cleveland Clinic, OH; Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (B.E.S., M.S.); Cardiovascular Group, Antisense Drug Discovery, Ionis Pharmaceuticals, Inc, Carlsbad, CA (R.G.L.); and Department of Internal Medicine-Section on Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.S.P.).
Daniela S AllendeFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute (A.D.G., R.C.S., A.L.B., R.N.H., A.C.B., D.F., R.Z., R.E.M., J.M.B.) and Department of Anatomical Pathology (D.S.A.), Cleveland Clinic, OH; Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (B.E.S., M.S.); Cardiovascular Group, Antisense Drug Discovery, Ionis Pharmaceuticals, Inc, Carlsbad, CA (R.G.L.); and Department of Internal Medicine-Section on Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.S.P.).
John S ParksFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute (A.D.G., R.C.S., A.L.B., R.N.H., A.C.B., D.F., R.Z., R.E.M., J.M.B.) and Department of Anatomical Pathology (D.S.A.), Cleveland Clinic, OH; Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (B.E.S., M.S.); Cardiovascular Group, Antisense Drug Discovery, Ionis Pharmaceuticals, Inc, Carlsbad, CA (R.G.L.); and Department of Internal Medicine-Section on Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.S.P.).
Matthew SpiteFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute (A.D.G., R.C.S., A.L.B., R.N.H., A.C.B., D.F., R.Z., R.E.M., J.M.B.) and Department of Anatomical Pathology (D.S.A.), Cleveland Clinic, OH; Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (B.E.S., M.S.); Cardiovascular Group, Antisense Drug Discovery, Ionis Pharmaceuticals, Inc, Carlsbad, CA (R.G.L.); and Department of Internal Medicine-Section on Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.S.P.).
J Mark BrownFrom the Department of Cellular and Molecular Medicine, Lerner Research Institute (A.D.G., R.C.S., A.L.B., R.N.H., A.C.B., D.F., R.Z., R.E.M., J.M.B.) and Department of Anatomical Pathology (D.S.A.), Cleveland Clinic, OH; Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (B.E.S., M.S.); Cardiovascular Group, Antisense Drug Discovery, Ionis Pharmaceuticals, Inc, Carlsbad, CA (R.G.L.); and Department of Internal Medicine-Section on Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.S.P.). brownm5@ccf.org.

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARK R CHANCE · 1987 to 2026
$142.3M
Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Project Two - Exercise Training Decreases Alcohol Drinking by an FGF21-Dependent MechanismP50AA024333 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI Thomas M McIntyre · 2016 to 2026
$19.6M
Resolution Mechanisms in Acute Inflammation: Resolution PharmacologyP01GM095467 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SERHAN, CHARLES NICHOLAS · 2011 to 2020
$14.8M
Non Alcoholic Steatohepatitis Clinical Research NetworkU01DK061732 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI Srinivasan Dasarathy · 2002 to 2026
$12.2M
Novel Therapies for Alcoholic HepatitisU01AA021893 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI MCCLAIN, CRAIG J., MCCULLOUGH, ARTHUR JOSEPH · 2012 to 2017
$6.0M
Role of Inflammation-Resolving Lipid Mediators In Ischemic RevascularizationR01HL106173 · NHLBI · UNIVERSITY OF LOUISVILLE · PI SPITE, MATTHEW R · 2011 to 2023
$5.7M
The Role of Hepatocyte ABCA1 in Lipid Mobilization and TransportR01HL119962 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI PARKS, JOHN S · 2013 to 2022
$3.9M
Forward genetic analysis of biliary system formationR01DK103637 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI SAKAGUCHI, TAKUYA · 2015 to 2025
$3.2M
Enzymatic Control of Trimethylamineoxide (TMAO)Induced AtherosclerosisR01HL122283 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI BROWN, JONATHAN MARK · 2014 to 2018
$2.0M
Role of resolvins in macrophage-mediated tissue repairF32HL136044 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SANSBURY, BRIAN EDWARD · 2017 to 2019
$190k
NCATS NIH HHS UL1 TR000439NCI NIH HHS P30 CA043703NHLBI NIH HHS F32 HL136044NHLBI NIH HHS R01 HL106173NHLBI NIH HHS R01 HL119962NHLBI NIH HHS R01 HL122283NIAAA NIH HHS P50 AA024333NIAAA NIH HHS U01 AA021893NIDDK NIH HHS R01 DK103637NIDDK NIH HHS U01 DK061732NIGMS NIH HHS P01 GM095467
6 · The paper itself

Abstract

objectiveHuman genetic variants near the FADS (fatty acid desaturase) gene cluster ( APPROACH AND

resultsHere, we specifically investigated the physiological role of the Δ-5 desaturase FADS1 in regulating diet-induced cardiometabolic phenotypes by treating hyperlipidemic LDLR (low-density lipoprotein receptor)-null mice with antisense oligonucleotides targeting the selective knockdown of

conclusionsThese results position

Indexed as

LipogenesisAnimalsAortaAortic DiseasesArachidonic AcidAtherosclerosisCells, CulturedDelta-5 Fatty Acid DesaturaseDisease Models, AnimalDyslipidemiasEicosapentaenoic AcidFatty Acid DesaturasesInflammationInflammation MediatorsLiverLiver X ReceptorsArachidonic AcidDelta-5 Fatty Acid DesaturaseEicosapentaenoic AcidFADS1 protein, humanFADS1 protein, mouseFatty Acid DesaturasesInflammation MediatorsLiver X ReceptorsOligonucleotides, AntisenseReceptors, LDLatherosclerosiseicosanoidslipogenesismacrophagesmetabolic diseases

Identifiers

PMID29074585
PMCPMC5746431

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.